Abstract: The human solute carrier family 19 member 1 (SLC19A1) is the gene coding for reduced folate carrier 1 (RFC1). In our previous work, we showed that the miR-595-related polymorphism, rs1051296 G>T, which was located in the 3 0 -untranslated region (3 0 -UTR) of SLC19A1, was associated with high methotrexate (MTX) plasma concentrations in patients with paediatric acute lymphoblastic leukaemia (ALL). This study aimed to investigate the role of miR-595 in the regulation of SLC19A1 expression and its effects on the cellular uptake and cytotoxicity of MTX in ALL CEM/C1 cells. Luciferase reporter assay was performed to validate SLC19A1 as a miR-595 target. RFC1 protein expression was determined via Western blotting. Intracellular MTX concentrations were measured by enzyme-linked immunosorbent assay (ELISA). Cell viability and apoptosis were assessed using Cell Counting Kit-8 (CCK-8) assay and flow cytometer, respectively. Compared to the negative control, miR-595 mimics induced a significant decrease in the relative luciferase activity by binding to the 3 0 -UTR of SLC19A1 harbouring the rs1051296 T allele (p < 0.01). Treatment of CEM/C1 cells with miR-595 mimics substantially reduced RFC1 protein expression, intracellular MTX levels, MTX-induced cytotoxicity and apoptosis rates compared to those of negative control. However, opposite results were observed in cells transfected with a miR-595 inhibitor. These findings suggested that miR-595 acts as a phenotypic regulator of MTX sensitivity in CEM/C1 cells by targeting SLC19A1. This study helped us to understand the mechanisms underlying the variable MTX responses observed in patients with ALL.
Acute lymphoblastic leukaemia (ALL) is the most common malignant disorder in children and has increasing incidence worldwide [1, 2] . ALL is characterized by malignant proliferation and accumulation of lymphoblasts in the bone marrow. The lymphoblasts continuously proliferate, interfere with the haematopoietic function of bone marrow and infiltrate other organs, ultimately leading to tissue damage and death [3] . Methotrexate (MTX) is a folate analogue that competitively inhibits dihydrofolate reductase (DHFR), an enzyme crucial for intracellular folate metabolism. Folate is essential for purine and pyrimidine base synthesis [4] . Therefore, MTX inhibits the DNA and RNA synthesis in cancer cells. MTX has excellent anti-proliferative effects and thus plays an important role in the consolidation and maintenance treatment of ALL, as well as prevention of extramedullary leukaemia. Advances in chemotherapy, including MTX treatment, have greatly improved ALL outcome, with greater than 80% 5-year survival rate for children with ALL [1, 2] . However, a considerable proportion of patients still do not achieve complete remission, and MTX resistance remains a major problem that limits the effectiveness of MTX in the ALL treatment [5, 6] .
MTX enters leukaemic cells primarily through active transport and is mediated by the reduced folate carrier 1 (RFC1), which is encoded by the human solute carrier family 19, member 1 (SLC19A1) gene [7] . Membrane transport of MTX provides sufficient amounts of the drug to promote the synthesis of polyglutamated metabolites required for high-affinity binding to and inhibition of target enzymes [8] . Transport by RFC1 is critical to the anti-tumour effects of MTX. A previous study showed that MTX transport and sensitivity were restored in transport-deficient Chinese hamster ovary cells expressing human SLC19A1 [9] . Down-regulation of SLC19A1 mRNA has been linked to impaired MTX transport and MTX resistance [10] . Several variants identified in the SLC19A1 gene that resulted in altered RFC1 function were associated with MTX responses and toxicities in ALL. The 80 G>A (rs1051266) polymorphism, a common non-synonymous mutation in exon 2 of SLC19A1, is the most widely studied SLC19A1 variant. In a clinical study of children with ALL conducted by Laverdiere et al. [11] , patients harbouring the rs1051266 AA genotype showed worse overall prognosis and more adverse outcome than GG genotype carriers.
MicroRNAs (miRNAs) are a class of endogenous, small non-coding RNAs with a length of about 22 nucleotides. miRNAs can regulate post-transcriptional expression of various genes by binding to the 3 0 -untranslated region (3 0 -UTR) of target mRNAs [12, 13] for drug sensitivity and disease susceptibility. Mishra PJ et al. [14] demonstrated that the 827 C>T polymorphism, which is located near the binding site of miR-24, alters DHFR expression and interferes with miR-24 function, ultimately leading to MTX resistance. In our previous work, the rs1051296 G>T polymorphism in the 3 0 -UTR of SLC19A1, which creates a miR-595 binding site, was found to be associated with higher plasma concentrations of MTX [15] . Iparraguirre et al. [16] noted that the rs4909237 TT genotype in miR-595 increases the risk of having elevated plasma MTX levels. The above findings suggested the potential role of miR-595 in SLC19A1 regulation; however, no functional experiments have been conducted to verify the potential mechanisms responsible for its regulatory effects. In this study, we investigated the role of miR-595 in the regulation of SLC19A1 expression and its effects on cellular uptake and MTX cytotoxicity in human ALL CEM-C1 cells.
Materials and Methods
Cell culture. Human ALL CEM-C1 cells were grown in RPMI-1640 medium supplemented with 10% foetal bovine serum (FBS; Gibco, Grand Island, NY, USA), 100 U/ml penicillin and 100 U/ml streptomycin (Beyotime Biotechnology, Shanghai, China). Cells were maintained at 37°C in a humidified atmosphere comprising 5% CO 2 and 95% air. CEM-C1 cells were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China) and genotyped for rs1051296 in 3 0 -UTR of SLC19A1 via sequencing.
RNA oligonucleotides and transfection. All RNA oligonucleotides (miR-595 mimic, miR-595 mimic -negative control, miR-595 inhibitor and miR-595 inhibitor -negative control) were synthesized by Invitrogen (Shanghai, China). MiR-595 mimic, miR-595 inhibitor and their corresponding negative controls (8 lmol/ml) were transiently transfected into CEM-C1 cells performed with Lipofectamine 2000 reagent (Invitrogen) following the manufacturer's instructions.
Luciferase reporter assays. The 3 0 -UTR sequences of SLC19A1 harbouring the rs1051296 T or G allele (Invitrogen) were cloned into pmir-Glo vectors (Promega, Beijing, China). The generated constructs were verified by sequencing. CEM-C1 cells at 70% confluence were seeded onto 96-well plates at 16 hr before transfection. Reporter plasmids and the miR-595 mimic or its negative control (NC) were cotransfected into CEM-C1 cells performed with Lipofectamine 2000 (Invitrogen). After 48 hr, Firefly and Renilla luciferase activities were measured using Dual-luciferase Reporter Assay System Kits (Promega) according to the manufacturer's instructions. Relative luciferase activity was calculated as the ratio between Firefly and Renilla luciferase activities normalized against the NC controls. Each sample was tested in sextuplicate.
Western blotting analysis. CEM-C1 cells were incubated for 48 hr after transfection with miR-595 mimic, miR-595 inhibitor and their negative controls. Cells were then harvested for protein extraction. Untransfected CEM-C1 cells were used as blank control (BC). Protein concentrations were determined using a bicinchoninic acid (BCA) assay. Total proteins were separated via 8% SDS-PAGE and subsequently transferred to a PVDF membrane. Anti-RFC (Abcam, Cambridge, MA, USA) or anti-GAPDH monoclonal antibody (Abcam) was used as primary antibody, and gout anti-rabbit IgG (Sigma, St. Louis, MO, USA) was used as secondary antibody. Proteins were visualized using enhanced chemiluminescence reagents.
Intracellular MTX concentration assays. Cells were seeded in 96-well plates at 24 hr before MTX treatment at a density of 5.0 9 10 5 cells per well. Cells were divided into the following treatment groups: BC group, miR-595 mimic group, miR-595 mimic NC group, miR-595 inhibitor group and miR-595 inhibitor NC group. Cells in each group were treated with varying concentrations of MTX (10, 20 and 40 ng/ ml) for 48 hr. Intracellular MTX levels were quantified via enzymelinked immunosorbent (ELISA) assay. The absorbance at 450 nm was recorded on a microplate reader. MTX concentrations were calculated based on the standard curve. All samples were measured in triplicate.
Proliferation assay. Cell proliferation assays were performed using Cell Counting Kit-8 (CCK8). The blank control and transfected CEM-C1 cells were treated with MTX at the low, middle and high concentrations for 24, 48 and 72 hr as described above. CCK8 solution (10 ll) was added to each well. Next, cells were incubated for 4 hr, and the absorbance at 450 nm was measured using a microplate reader. The inhibition rate of cancer cells was calculated as {[(OD control -OD blank )-(OD treated -OD blank )]/(OD control -OD blank )} 9 100. All experiments were repeated in triplicate.
Apoptosis assays. The blank control and transfected CEM-C1 cells were cultured in six-well plates and treated with increasing concentrations of MTX (10, 20 and 40 ng/ml), after which cells were incubated at 37°C and 5% CO 2 for 48 hr. Annexin V-FITC Apoptosis Detection Kit (BD, San Jose, CA, USA) was used to detect apoptosis according to the manufacturer's instructions. Apoptotic cells were analysed on a flow cytometer (BD). All experiments were repeated in duplicate.
Statistical analysis. Data were expressed as mean AE S.D. unless otherwise indicated. Comparisons between two groups were performed using unpaired two-tailed Student's t-test. Graphpad Prism Software version 4.0 (GraphPad Software, Inc., La Jolla, CA, USA) was used for all statistical analyses. p < 0.05 was considered statistically significant.
Results
MiR-595 targets SLC19A1 to regulate its expression. To examine the effect of the rs1051296 G>T polymorphism on the binding interaction between miR-595 and the 3 0 -UTR of SLC19A1, we constructed reporter plasmids harbouring the rs1051296 T or G allele in the 3 0 -UTR of SLC19A1. Dual-luciferase reporter assays were then performed to test whether SLC19A1 is a miR-595 target. As shown in fig. 1 , treatment miR-595 mimics induced a significant reduction in relative luciferase activity for the construct harbouring the rs1051296 T allele when compared to NC treatment in CEM/C1 cells (p < 0.05). In the construct harbouring rs1051296 G allele, no significant difference in relative luciferase activity was observed between miR-595 mimics and NC groups. These results suggested that miR-595 could bind to the 3 0 -UTR of SLC19A1 and that the rs1051296 G>T polymorphism affects their binding affinity. Next, gain-and-loss experiments of miR-595 and Western blotting assay were performed to examine the regulatory role of miR-595 in the protein expression of RFC1 in CEM/C1 cells harbouring the rs1051296 TT genotype. As shown in fig. 2 , introduction of miR-595 mimics in CEM/C1 cells substantially decreased RFC1 protein expression, whereas treatment with miR-595 inhibitor up-regulated protein levels of RFC1 compared with the NC group. These findings suggested that miR-595 acts as a negative regulator of RFC1.
MiR-595 up-regulation reduced cellular uptake of MTX in CEM/C1 cells. To explore the effects of miR-595 on the cellular uptake of MTX in CEM/C1 cells, we performed gain-and-loss experiments of miR-595 and measured the intracellular MTX concentrations using an ELISA assay. As shown in fig. 3 , intracellular MTX levels in CEM/C1 cells transfected with miR-595 mimics were significantly lower than those in controls after 48 hr of incubation with three different concentrations of MTX (10, 20 and 40 ng/ml) for 48 hr. However, CEM/C1 cells transfected with miR-595 inhibitors showed significantly higher intracellular levels of MTX compared with controls. These results demonstrated that miR-595 upregulation can reduce MTX uptake, while miR-595 downregulation can enhance MTX uptake into cancer cells.
MiR-595 up-regulation decreased sensitivity of CEM/C1 cells to MTX. To functionally characterize the effects of miR-595 on MTX cytotoxicity, we determined changes in cell viability upon MTX treatment by performing CCK-8 assays. Compared with NC, miR-595 up-regulation resulted in significantly reduced inhibition rates of CEM/C1 cells incubated with varying doses of MTX for 48 hr ( fig. 4A ). As expected, miR-595 down-regulation significantly increased inhibition rates of CEM/C1 cells compared with cells treated with NC. Considering that apoptosis is one of the mechanisms by which MTX exerts its antitumour effects, we next investigated the potential role of miR-595 in MTX-induced apoptosis of CEM/C1 cells. Flow cytometry analysis revealed that in all MTX concentrations, apoptosis indices in CEM/C1 cells were lower in the miR-595 mimic groups treated with various MTX concentrations than those in controls. An opposite trend was observed in miR-595 inhibitor groups after 48 hr of treatment ( fig. 4B ). These results indicated that miR-595 up-regulation reduced the cytotoxic effects of MTX on CEM/C1 cells by blocking apoptosis, whereas miR-595 down-regulation increased the sensitivity of CEM/C1 cells to MTX by promoting apoptosis.
Discussion
MTX acts by blocking DNA synthesis in cancer cells and thus constitutes an important component of the standard chemotherapy protocol for ALL. However, studies have shown high variability in the pharmacokinetics and pharmacodynamics of MTX. The observed variation in MTX responses of patients with ALL could be partly attributed to genetic and epigenetic factors involved in the regulation of transporters, metabolic enzymes and drug targets. Our previous study showed that rs1051296 G>T, a miR-595-related polymorphism in the 3 0 -UTR of SLC19A1, was associated with elevated plasma MTX concentrations in children with ALL. In the present study, we further demonstrated that miR-595 suppressed cellular uptake and inhibited cytotoxic effects of MTX by targeting SLC19A1 in CEM/C1 cells. Recent studies have demonstrated the involvement of miR-595 in the progression of several diseases. Alkhatabi et al. [17] showed that miR-595 expression is significantly downregulated in patients with higher risk of myelodysplasia. Hao et al. [18] reported significant up-regulation of miR-595 in glioblastoma tissues and cells and showed that miR-595 significantly promoted glioblastoma cell proliferation by targeting SOX7. Krissansen et al. [19] demonstrated that miR-595 impaired epithelial tight junctions by inhibiting the expression of neural cell adhesion molecule-1 and fibroblast growth factor receptor 2, which could thus serve as biomarkers for active inflammatory bowel disease. MiR-595 can also modulate drug sensitivity. Tian et al. [20] demonstrated that miR-595 induced cisplatin sensitivity in ovarian cancer cells by targeting ABCB1. However, the relationship between miR-595 and drug sensitivity in leukaemia remains to be investigated. In the present study, we found that miR-595 up-regulation significantly reduced the inhibition and apoptosis rates of CEM/C1 cells treated with three different MTX concentrations. On the other hand, miR-595 down-regulation significantly increased inhibition and apoptosis rates in CEM/C1 cells. These findings suggested that miR-595 can regulate MTX sensitivity in CEM/C1 cells.
RFC1 is responsible for the intracellular transport of folates and antifolate drugs. As a major transporter of MTX into cancer cells, RFC1 expression and activity are closely linked to the efficacy of MTX treatment in cancer therapy [21] . As early as 1962, Fischer et al. [22] proposed the loss of active transport of MTX as a mechanism underlying MTX resistance in L5178Y leukaemic cells. Since then, an increasing number of studies showed that loss of RFC is accompanied by MTX resistance in cultured cell lines [23] [24] [25] . In the current study, we showed that treatment with miR-595 mimics significantly inhibited the luciferase activity of a reporter construct harbouring the rs1051296 T allele, but not the construct harbouring the G allele in the 3 0 -UTR of SLC19A1. These findings suggested that SLC19A1 can be a direct target of miR-595 in ALL and that the rs1051296 T>G polymorphism can affect the interaction between miR-595 and SLC19A1. Our data also showed that protein expression of RFC1 was down-regulated in CEM/C1 cells but was significantly up-regulated by treatment with miR-595 inhibitors when compared with the controls. Therefore, miR-595 up-regulation can potentially impair RFC1 function in ALL.
Given that miR-595 can inhibit RFC1 expression, we investigated the effects of miR-595 on RFC1-mediated transport of MTX. Results indicated that the intracellular MTX concentrations obviously decreased upon the treatment with miR-595 mimics. On the other hand, opposite results were obtained upon treatment with miR-595 inhibitors. These findings suggested that miR-595 reduced cellular uptake of MTX and thus further explain the attenuated sensitivity to MTX in CEM/C1 cells overexpressing miR-595. Only a few studies have investigated the effects of miRNAs on drug concentrations. Recently, Chen Q and colleagues reported that miR-3190-5p elevated intracellular concentration of 5-fluorouracil (5-FU) and enhanced the sensitivity of colorectal cancer cells to 5-FU by inhibiting ABCC4, an efflux transporter responsible for the extracellular transport of many endogenous substances and drugs [26] .
Our study has several limitations. Firstly, we did not investigate whether RFC1 knockdown and over-expression influenced the inhibitory effects of miR-595 on MTX cytotoxicity. Secondly, studies on the role of miR-595 in the regulation of MTX sensitivity in other leukaemic cell lines are required to support our findings. Thirdly, our study lacks in vivo evidence of the role of miR-595 in MTX sensitivity.
In summary, we demonstrated that miR-595 inhibits RFC1 expression by binding to the 3 0 -UTR of SLC19A1. Furthermore, our results implicated miR-595 as a phenotypic regulator of MTX sensitivity in CEM/C1 cells. The study helped us to understand the mechanisms underlying the observed variable MTX responses in patients with ALL.
